Medical device firm Medtronic (MDT) has managed to fare better lately; shares of the company have climbed 20% over the last year. Medtronic develops everything from pacemakers and defibrillators to stents and insulin pumps. Heart products have traditionally contributed around half of MDT's sales, a solid positioning given the sheer number of people around the world who suffer from heart disease and related ailments.
Innovation has been a key to Medtronic's success. The firm spends a considerable chunk of effort on R&D, and it's managed to build out an attractive pipeline of medical device products through a combination of internal investment and tech acquisitions from other firms. While MDT's offerings should help buoy shares in the near-term, looking longer-term, a rising tide is likely to lift all ships in the medical device business.
From a financial standpoint, Medtronic is in solid shape, with a reasonable amount of balance sheet leverage and plenty of liquidity to play with. Couple that with impressive free cash flow generation, and investors have a recipe for a dividend hike in the next quarter. Right now, MDT pays a 26-cent dividend that equates to a 2.2% yield at current price levels.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV